CD47 and glioblastoma: Exosomes with a targeted approach (e.g., CD47 targeting) have shown promising outcomes in solid tumors of deadly cancers, including GBM (glioblastoma), PDAC (pancreatic ductal adenocarcinoma), and TNBC (triple-negative breast cancer) [33,34,35].